Expertise in
37
conditions

Dr. Sarina A. Piha-Paul

Oncology
Office
1515 Holcombe Blvd Unit 455, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
37
conditions
Office
1515 Holcombe Blvd Unit 455, 
Houston, TX 

Overview

Sarina Piha-Paul is an Oncologist practicing medicine in Houston, Texas.

Dr. Piha-Paul is highly rated in 37 conditions, according to our data. Her clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Adult Soft Tissue Sarcoma, Melanoma, Colorectal Cancer, and Colonoscopy.

She is actively involved in clinical research, co-authoring 281 peer reviewed articles and participating in 36 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Office
1515 Holcombe Blvd Unit 455, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
Study Drug: SGN-B6A
Study Phase: Phase 1
Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
Enrollment Status: Terminated
Publish Date: July 22, 2026
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of the PARP Inhibitor Talazoparib in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)
Phase II Study of the PARP Inhibitor Talazoparib in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2026
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications
Enrollment Status: Terminated
Publish Date: May 15, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Bevacizumab, Cetuximab, Temsirolimus, Valproic Acid
Study Phase: Phase 1
A Phase 1, First-in-Human Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies
A Phase 1, First-in-Human Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors
A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2026
Intervention Type: Drug, Biological
Study Drugs: Pembrolizumab, Clostridium Novyi-NT, Doxycycline
Study Phase: Phase 1
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy.
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy.
Enrollment Status: Completed
Publish Date: November 20, 2025
Intervention Type: Combination product
Study Phase: Phase 2
A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers
A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: TT-00420
Study Phase: Phase 1
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 16, 2024
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

281 Total Publications

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.
Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.
Journal: Journal for immunotherapy of cancer
Published: July 27, 2026
Similar Doctors
Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Office

1400 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.3 miles away)
713-792-2813
Languages Spoken:
English
See accepted insurances

Hagop Kantarjian is an Oncologist practicing medicine in Houston, Texas. Dr. Kantarjian is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Splenectomy.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-8850
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Neeta Somaiah is an Oncologist practicing medicine in Houston, Texas. Dr. Somaiah is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Hepato-Pancreato-Biliary Surgery.

Expertise in
32
conditions
Expertise in
32
conditions
Referral may be required

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-2860
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Luis Fayad is an Oncologist practicing medicine in Houston, Texas. Dr. Fayad is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Sarina A. Piha-Paul

How do I make an appointment with Dr. Sarina A. Piha-Paul?

You can book an appointment with Dr. Sarina A. Piha-Paul by calling their office at 713-563-0181. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sarina A. Piha-Paul a top-rated expert for PIK3CA-Related Overgrowth Spectrum?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sarina A. Piha-Paul is classified as an Elite expert for PIK3CA-Related Overgrowth Spectrum, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sarina A. Piha-Paul specialize in?

While Dr. Sarina A. Piha-Paul is a Oncology, they have specific expertise in PIK3CA-Related Overgrowth Spectrum, Adult Soft Tissue Sarcoma, and Melanoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Sarina A. Piha-Paul participate in research or clinical trials?

Yes. Dr. Sarina A. Piha-Paul has published 281 articles and abstracts on conditions like PIK3CA-Related Overgrowth Spectrum. You can view a list of Dr. Sarina A. Piha-Paul's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sarina A. Piha-Paul accept my insurance?

Dr. Sarina A. Piha-Paul accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-563-0181 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Piha-Paul's expertise for a condition
ConditionClose
View All 31 Advanced Conditions
View All 90 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile